172 related articles for article (PubMed ID: 22417857)
41. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
[TBL] [Abstract][Full Text] [Related]
42. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY; Oh YL
Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
[TBL] [Abstract][Full Text] [Related]
43. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
44. Correlation of HER 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma.
Ramadan SS; Yapicier O; Kıhtır S; Erdemır A; Doğan TH; Uskent I; Onat H; Cakmakçi M
Turk Patoloji Derg; 2011; 27(3):196-203. PubMed ID: 21935868
[TBL] [Abstract][Full Text] [Related]
45. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens.
Susini T; Bussani C; Marini G; Nori J; Olivieri S; Molino C; Bianchi S; Vezzosi V; Paglierani M; Giachi M; Borrani E; Scarselli G
Gynecol Oncol; 2010 Feb; 116(2):234-9. PubMed ID: 19919879
[TBL] [Abstract][Full Text] [Related]
46. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
[TBL] [Abstract][Full Text] [Related]
47. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
48. Her-2/neu and breast cancer.
Kaptain S; Tan LK; Chen B
Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
[TBL] [Abstract][Full Text] [Related]
49. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
50. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
[TBL] [Abstract][Full Text] [Related]
51. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
52. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
53. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
54. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
55. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
[TBL] [Abstract][Full Text] [Related]
56. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
Pauletti G; Godolphin W; Press MF; Slamon DJ
Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
[TBL] [Abstract][Full Text] [Related]
57. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
58. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
60. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
